Therapy Areas: Inflammatory Diseases
Palatin Technologies Doses First Human Subjects in Clinical Study of Investigational Melanocortin Receptor 1 Agonist for Treatment of Inflammatory Bowel Diseases
7 February 2018 - - Cranbury, New Jersey-based peptide therapeutics developer Palatin Technologies, Inc. (NYSE American: PTN) has dosed the first healthy subjects in a Phase 1 clinical study of PL-8177, a selective melanocortin receptor 1 (MC1r) agonist peptide for the treatment of ulcerative colitis and other inflammatory bowel diseases, the company said.
The Phase 1 study, designed to enroll up to 52 healthy volunteers, is a randomized, double-blind, placebo-controlled, single and multiple ascending dose study intended to evaluate the safety and tolerability of PL-8177 administered via subcutaneous injection.
PL-8177 is Palatin's lead clinical development candidate. Evolving research suggests that the MC1r system plays an important role in immunoregulation, including resolution of innate pro-inflammatory immune responses.
PL-8177 is a synthetic cyclic heptapeptide with demonstrated efficacy in animal inflammatory bowel disease models. Palatin has developed an oral formulation of PL-8177 that has been validated in animal studies, which is scheduled to be explored in future clinical investigations.
Palatin is developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. The company's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.